Prediction of sustained virologic responses to combination therapy of pegylated interferon-α and ribavirin in patients with chronic hepatitis C infection

Journal of Family and Community Medicine

Volumn 20, Issue 1, 2013, Pages 35-40

  Ismail, Mona ^a  

^a IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

Chronic hepatitis C; Saudi; sustained virologic response; treatment response predictors

Indexed keywords

EID: 84896126011     PISSN: 22308229     EISSN: 2229340X     Source Type: Journal    
DOI: 10.4103/2230-8229.108182     Document Type: Article

References (28)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
2. Heintges T, Wands JR. Hepatitis C virus: Epidemiology and transmission. Hepatology 1997;26:521-6.
3. De Filippi F, Colombo M. Treatment of chronic hepatitis C. J Biol Regul Homeost Agents 2003;17:133-7.
4. Coverdale SA, Khan MH, Byth K, Lin R, Weltman M, George J, et al. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol 2004;99:636-44.
5. McOmish F, Yap PL, Dow BC, Follett EA, Seed C, Keller AJ, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: An international collaborative survey. J Clin Microbiol 1994;32:884-92.
6. al Faleh FZ, Huraib S, Sbeih F, al-Karawi M, al-Rashed R, al-Mofleh IA, et al. Hepatitis C virus genotypes in patients with chronic liver disease and haemodialysis patients from Saudi Arabia. J Viral Hepat 1995;2:293-6.
7. Abdo AA, Sanai FM. Predictors of sustained virologic response in hepatitis C genotype 4: Beyond the usual suspects. Ann Saudi Med 2009;29:1-3.
8. Dienstag JL, McHutchison JG. American Gastroenterological Association Technical Review on the management of hepatitis C. Gastroenterology 2006;130:231-64.
9. Lee SS, Abdo AA. Predicting antiviral treatment response in chronic hepatitis C: How accurate and how soon?. J Antimicrob Chemother 2003;51:487-91.
10. Poordad F, Reddy KR, Martin P. Rapid virologic response: A new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008;46:78-84.
11. Kamal SM, Nasser IA. Hepatitis C genotype 4: What we know and what we don′t yet know. Hepatology 2008;47:1371-83.
12. Al-Faleh FZ, Hadad Q, Khuroo MS, Aljumah A, Algamedi A, Alashgar H, et al. Peginterferon á-2b plus ribavirin compared with interferon á-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004;24:568-74.
13. Kamal SM, El Kamary SS, Shardell MD, Hashem M, Ahmed IN, Muhammadi M, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatolgy 2007;46:1732-40.
14. Gad RR, Males S, El Makhzangy H, Shouman S, Hasan A, Attala M, et al. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver Int 2008;28:1112-9.
15. Itraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994;20:15-20.
16. Hasan F, Asker H, Al-Khaldi J, Siddique I, Al-Ajmi M, Owaid S, et al. Peginterferon Alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004;99:1733-7.
17. Al Ashgar H, Helmy H, Khan MQ, Al Kahtani K, Al Quaiz M, Rezeig M, et al. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4. Ann Saudi Med 2009;29:4-14.
18. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000;31:211-8.
19. Zeuzem S, Hulcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginteferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993-9.
20. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999;29:1215-9.
21. Clouston AD, Jonsson JR, Purdie DM, Macdonald GA, Pandeya N, Shorthouse C, et al. Steatosis and chronic hepatitis C: Analysis of fibrosis and stellate cell activation. J Hepatol 2001;34:314-20.
22. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64.
23. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007;46:37-47.
24. Ge D, Fellay J, Thompson AJ, Thompson AJ, Simon JS, Shianna KV, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
25. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virological response. Gastroenterology 2010;139:821-7.
26. Asselah T, De Muynck S, Broët P, Masliah-Planchon J, Blanluet M, Bièche, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012;56:527-32.
27. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
28. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.